EUVIMEDEUVIMED entdecken
Crossref

Potential mitigating impact of a dipeptidyl peptidase-IV inhibitor, vildagliptin, on oxazolone-induced ulcerative colitis: Targeting the role of PI3K/AKT/mTOR and AMPK/Nrf2 signaling pathways

Marwa Mahmoud Awad, Rehab M El-Gohary, Sarah Ibrahim, Muhammad Tarek Abdel Ghafar, Eman E Farghal, Alshimaa Aboalsoud, Rehab Ahmed Ahmed El-Shaer

International Immunopharmacology · 2024-05 · 133 · 112110

DOI: 10.1016/j.intimp.2024.112110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-05. Verfasst von Marwa Mahmoud Awad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Physiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Electronic address: Marwa.saleh@med.tanta.edu.eg. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Oxazolone, Signal Transduction, Vildagliptin. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: Tanta University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Growing evidence suggests that phosphoinositide 3-kinase (PI3K) and adenosine monophosphate-activated protein kinase (AMPK) signaling cascades are critical in ulcerative colitis (UC) pathophysiology by influencing gut mucosal inflammation. Recently, the coloprotective properties of dipeptidyl peptidase-IV (DPP-IV) inhibitors have emerged. Thus, this study assessed for the first time the potential mitigating impact of a DPP-IV inhibitor, vildagliptin (Vilda), on oxazolone (OXZ)-induced colitis in rats, targeting the role of PI3K/AKT/mTOR and AMPK/Nrf2 pathways. Thirty-two adult Albino rats were divided into four groups: control, Vilda (10 mg/kg/day orally), OXZ (300 µL of 5 % OXZ in 50 % aqueous ethanol solution introduced once into the colon via catheter), and Vilda+OXZ. Inflammatory cytokines (interleukin 13, tumor necrosis factor-α, interleukin 10), oxidative/endoplasmic reticulum stress markers (myeloperoxidase, reduced glutathione, catalase, CHOP), mitochondrial reactive oxygen species, adenosine triphosphate levels, and mitochondrial transmembrane potential were estimated. p-AMPK, p-AKT, beclin-1, and SQSTM1 levels were immunoassayed. Nrf2, PI3K, and mTOR expression levels were quantified using the real-time polymerase chain reaction. Furthermore, p-NF-ĸBp65 and LC3II immunoreactivity were evaluated. Vilda administration effectively ameliorated OXZ-induced colitis, as evidenced by the reduced Disease Activity Index, macroscopic colon damage score, colon weight/length ratio, ulcer index, and histopathological and electron microscopic changes in the colon tissues. Vilda treatment also counteracted OXZ-triggered inflammation, oxidative/endoplasmic reticulum stress, mitochondrial dysfunction, and enhanced autophagy in the colon. Vilda substantially suppressed PI3K/AKT/mTOR and activated the AMPK/Nrf2 pathway. Vilda has potent coloprotective and anti-ulcerogenic properties, primarily attributed to its antiinflammatory, antioxidant, and modulatory impact on mitochondrial dysfunction and autophagy activity. These effects were mostly mediated by suppressing PI3K/AKT/mTOR and activating AMPK/Nrf2 signaling cascades, suggesting a potential role of Vilda in UC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeOxazoloneSignal TransductionVildagliptinAnimalsMaleRatsAMP-Activated Protein KinasesAnti-Inflammatory AgentsColonCytokinesDipeptidyl-Peptidase IV InhibitorsDisease Models, AnimalNF-E2-Related Factor 2Oxidative StressPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Stichwörter der Autor:innen

AutophagyMitochondrial dysfunctionSignalling pathwaysUlcerative colitisVildagliptin

Substanzen

AMP-Activated Protein KinasesAnti-Inflammatory AgentsCytokinesDipeptidyl-Peptidase IV InhibitorsmTOR protein, ratNF-E2-Related Factor 2Nfe2l2 protein, ratOxazolonePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • Physiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Electronic address: Marwa.saleh@med.tanta.edu.eg.
  • Medical Biochemistry Department, Faculty of Medicine,Tanta University,Tanta, Egypt. Electronic address: Rehab.elgohary@med.tanta.edu.eg.
  • Human Anatomy and Embryology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Electronic address: Sara.ibrahim@med.tanta.edu.eg.
  • Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Electronic address: mohamed.abdelghafar@med.tanta.edu.eg.
  • Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Electronic address: eman.farghal@med.tanta.edu.eg.
  • Pharmacology Depatrtment, Faculty of Medicine, Tanta University, Tanta, Egypt. Electronic address: alshimaa.taha@med.tanta.edu.eg.

Förderung

  • Tanta University

Zitieren

APA

Awad, M. M., El-Gohary, R. M., Ibrahim, S., Abdel Ghafar, M. T., Farghal, E. E., Aboalsoud, A., & El-Shaer, R. A. A. (2024). Potential mitigating impact of a dipeptidyl peptidase-IV inhibitor, vildagliptin, on oxazolone-induced ulcerative colitis: Targeting the role of PI3K/AKT/mTOR and AMPK/Nrf2 signaling pathways. International Immunopharmacology, 133, 112110. https://doi.org/10.1016/j.intimp.2024.112110

Vancouver

Awad MM, El-Gohary RM, Ibrahim S, Abdel Ghafar MT, Farghal EE, Aboalsoud A, et al. Potential mitigating impact of a dipeptidyl peptidase-IV inhibitor, vildagliptin, on oxazolone-induced ulcerative colitis: Targeting the role of PI3K/AKT/mTOR and AMPK/Nrf2 signaling pathways. International Immunopharmacology. 2024;133:112110. doi:10.1016/j.intimp.2024.112110

BibTeX
@article{Awad2024,
  author = {Awad, Marwa Mahmoud and El-Gohary, Rehab M and Ibrahim, Sarah and Abdel Ghafar, Muhammad Tarek and Farghal, Eman E and Aboalsoud, Alshimaa and El-Shaer, Rehab Ahmed Ahmed},
  title = {Potential mitigating impact of a dipeptidyl peptidase-IV inhibitor, vildagliptin, on oxazolone-induced ulcerative colitis: Targeting the role of PI3K/AKT/mTOR and AMPK/Nrf2 signaling pathways},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {133},
  pages = {112110},
  doi = {10.1016/j.intimp.2024.112110}
}
Kostenlos starten →